IGC
IGC Pharma Inc (IGC)
Healthcare • NYSE MKT • $0.31-2.54%
- Symbol
- IGC
- Exchange
- NYSE MKT
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $0.31
- Daily Change
- -2.54%
- Market Cap
- $30.73M
- Trailing P/E
- N/A
- Forward P/E
- -3.66
- 52W High
- $0.50
- 52W Low
- $0.24
- Analyst Target
- $4.13
- Dividend Yield
- N/A
- Beta
- 0.50
IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's. Its pre-clinical stage product candidate includes TGR-63 and IGC-M3 to treat Alzheimer's disease. In addition, the company develops MINT-AD, an AI-driven assistant for healthcare providers. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. IGC Pharma, Inc. was incorporated in 2005 and is headquartered in Potomac, Maryland.
Company websiteResearch IGC on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.